Guidelines for Monitoring Efficacy and Toxicity Responses in Clinical Trials
From MaRDI portal
Publication:4844294
DOI10.2307/2533451zbMath0825.62790OpenAlexW2334059279WikidataQ60700028 ScholiaQ60700028MaRDI QIDQ4844294
Vernon T. Farewell, Richard J. Cook
Publication date: 28 November 1995
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.2307/2533451
Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)
Related Items (10)
Interim evaluation of efficacy or futility in group‐sequential trials with multiple co‐primary endpoints ⋮ Exact power calculations for detecting hypotheses involving two correlated binary outcomes ⋮ Controlling bivariate categorical processes using scan rules ⋮ Tree-structured analysis of treatment effects with large observational data ⋮ Comparison of numerical algorithms for bivariate sequential tests based on marginal criteria ⋮ Sequential tests of multiple hypotheses controlling type I and II familywise error rates ⋮ Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials ⋮ A Rejection Principle for Sequential Tests of Multiple Hypotheses Controlling Familywise Error Rates ⋮ An Adaptive Approach to Implementing Bivariate Group Sequential Clinical Trial Designs ⋮ Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes
Uses Software
This page was built for publication: Guidelines for Monitoring Efficacy and Toxicity Responses in Clinical Trials